Long-term outcomes after medical and interventional therapy of critical limb ischemia

European Journal of Internal Medicine

Volumn 20, Issue 6, 2009, Pages 616-621

  Lawall, Holger ^a   Gorriahn, Hannah ^a   Amendt, Klaus ^b   Ranft, Jürgen ^c   Bramlage, Peter ^d   Diehm, Curt ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Diakonie Krankenhaus Mannheim   (Germany)

^c Knappschaftskrankenhaus Bottrop   (Germany)

^d Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

Author keywords

Antibiotic treatment; Critical limb ischemia; Intervention; Peripheral arterial disease; Prostanoids

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ILOPROST; PROSTAGLANDIN E1;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DISEASE COURSE; ENDOVASCULAR SURGERY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LIMB AMPUTATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; TISSUE NECROSIS; TREATMENT OUTCOME; WOUND HEALING;

AGED; CRITICAL ILLNESS; FEMALE; HUMANS; ISCHEMIA; LEG; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349422157     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.06.002     Document Type: Article

References (27)

1. Abul-Khoudoud O. Diagnosis and risk assessment of lower extremity peripheral arterial disease. J Endovasc Ther 13 Suppl 2 (2006) II10-II18
2. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halparin J.L., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 113 (2006) e463-e654
3. AdamDJ, Beard JD, Cleveland T, BASIL trial investigations et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;366:1925-34.
4. Norgren L., Hiatt W.R., Dormandy J.A., Neklar M.R., Harris K.A., Fowles F.G.R., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33 Suppl 1 (2007) S1-S75
5. Heidrich H., Rogatti W., Altmann E., Bauersachs R., Diehm C., Fahrig C., et al. [DRG-based cost analysis of inpatient conservative treatment of PAD stage III/IV]. VASA 32 (2003) 235-240
6. Hooi J.D., Kester A.D., Stoffers H.E., Overdijk M.M., van Ree J.W., and Knottnerus J.A. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 153 (2001) 666-672
7. Catalano M. Epidemiology of critical limb ischaemia: north Italian data. Eur J Med 2 (1993) 11-14
8. Ebskov L.B., Schroeder T.V., and Holstein P.E. Epidemiology of leg amputation: the influence of vascular surgery. Br J Surg 81 (1994) 1600-1603
9. Garcia L.A. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Ther 13 Suppl 2 (2006) II3-II9
10. Dormandy J., Heeck L., and Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 12 (1999) 142-147
11. Bailey C.M., Saha S., Magee T.R., and Galland R.B. A 1 year prospective study of management and outcome of patients presenting with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 25 (2003) 131-134
12. Bertele V., Roncaglioni M.C., Pangrazzi J., Terzian E., and Tognoni E.G. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc Surg 18 (1999) 401-410
13. Lepantalo M., and Matzke S. Outcome of unreconstructed chronic critical leg ischaemia. Eur J Vasc Endovasc Surg 11 (1996) 153-157
14. Faglia E., Clerici G., Clerissi J., Gabrielli L., Losa S., Mantero M., et al. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg 32 (2006) 484-490
15. Jamsen T., Manninen H., Tulla H., and Matsi P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J Vasc Interv Radiol 13 (2002) 455-463
16. Gschwandtner M.E., Minar E., Ahmadi A., Haumer M., Hülsmann M., Maca T., et al. Impact of different therapeutic alternatives in treatment of severe limb ischemia: experiences on 190 consecutive patients at a department of medical angiology. VASA 28 (1999) 271-278
17. Heidrich H., Ranft J., Peters A., and Rummel S. [Early and late resultsafter intravenous Prostavasin Therapy in peripheral-arterial perfusion disorders with pain at rest and necrosis]. VASA 20 Suppl (1987) 202-203
18. Balzer K., Bechara G., Bisler H., Clevert H.D., Diehm C., Heisig G., et al. Placebo-kontrollierte, doppel-blinde Multicenterstudie zur Wirksamkeit von Iloprost bei der Behandlung ischämischer Ruheschmerzen von Patienten mit peripheren arteriellen Durchblutungsstörungen. VASA 20 Suppl (1987) 379-381
19. Brock F.E., Abri O., Baitsch G., Beckara G., Bed K., Corovic D., Diehm C., et al. [Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative]. Schweiz Med Wochenschr 120 (1990) 1477-1482
20. Diehm C., Abri O., Baitsch G., Beckara G., Bed K., Breddin M.K., et al. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study]. Dtsch Med Wochenschr 114 (1989) 783-788
21. Diehm C., Hibsch-Miller C., and Stammler F. Intravenöse Prostaglandin E1-Therapie bei Patienten mit peripherer arterieller Verschlusskrankheit (AVK) im Stadium III: Eine doppelblinde, placebo-kontrollierte Studie. In: Heinrich H., Bohme H., and Rogatti W. (Eds). Prostaglandin E1-Wirkungen und therapeutische Wirksamheit (1988), Springer-Verlag, Heidelberg 133-143
22. The Ciprostene Study Group. The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. J Clin Pharmacol 31 (1991) 81-87
23. U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. Eur J Vasc Surg 5 (1991) 511-516
24. Guilmot J., Diot E., and for the French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analoque of prostacyclin: results of a French Multicentre trial. Drug Invest 3 (1991) 351-359
25. Norgren L., Alwmark A., Angqvist K.A., Hedberg B., Bergquist D., Takolonda R., et al. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study. Eur J Vasc Surg 4 (1990) 463-467
26. Sakaguchi S. Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. Int Angiol 3 (1984) 39-42
27. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD. Eur Heart J 28 (2007) 88-136